This study is designed to follow up patients, who have achieved complete clearance of AK lesions (lesion count of 0) at Day 57 in the PEP005-020 study, over a 12 month period to assess both recurrence of Actinic Keratosis (AK) lesions and long term safety in the selected treatment area.

Inclusion

• Patient has provided informed consent documented by signing the Informed Consent Form (ICF) prior to any study-related procedures
• Patient achieved complete clearance of AK lesions (lesion count of 0) in the selected treatment area at the Day 57 visit in study PEP005-020

Exclusion

• Concurrent participation in another research study which would involve the selected treatment area (except for any post-study follow-up visits for previous Peplin AK study)
• Early termination from study PEP005-020

Patients who have achieved complete clearance of AK lesions (lesion count of 0) at Day 57 in study PEP005-020